1ft1: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
|PDB= 1ft1 |SIZE=350|CAPTION= <scene name='initialview01'>1ft1</scene>, resolution 2.25Å | |PDB= 1ft1 |SIZE=350|CAPTION= <scene name='initialview01'>1ft1</scene>, resolution 2.25Å | ||
|SITE= | |SITE= | ||
|LIGAND= <scene name='pdbligand=ZN:ZINC ION'>ZN</scene> | |LIGAND= <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene> | ||
|ACTIVITY= | |ACTIVITY= | ||
|GENE= CDNA ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=10116 Rattus norvegicus]) | |GENE= CDNA ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=10116 Rattus norvegicus]) | ||
|DOMAIN= | |||
|RELATEDENTRY= | |||
|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1ft1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1ft1 OCA], [http://www.ebi.ac.uk/pdbsum/1ft1 PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=1ft1 RCSB]</span> | |||
}} | }} | ||
| Line 24: | Line 27: | ||
[[Category: Beese, L S.]] | [[Category: Beese, L S.]] | ||
[[Category: Park, H W.]] | [[Category: Park, H W.]] | ||
[[Category: cancer therapeutic]] | [[Category: cancer therapeutic]] | ||
[[Category: g protein]] | [[Category: g protein]] | ||
| Line 32: | Line 34: | ||
[[Category: transferase]] | [[Category: transferase]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Mar 30 20:29:42 2008'' | ||
Revision as of 17:29, 30 March 2008
| |||||||||||||
| 1ft1, resolution 2.25Å | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ligands: | ZN | ||||||||||||
| Gene: | CDNA (Rattus norvegicus) | ||||||||||||
| Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||||||||
CRYSTAL STRUCTURE OF PROTEIN FARNESYLTRANSFERASE AT 2.25 ANGSTROMS RESOLUTION
Overview
Protein farnesyltransferase (FTase) catalyzes the carboxyl-terminal lipidation of Ras and several other cellular signal transduction proteins. The essential nature of this modification for proper function of these proteins has led to the emergence of FTase as a target for the development of new anticancer therapy. Inhibition of this enzyme suppresses the transformed phenotype in cultured cells and causes tumor regression in animal models. The crystal structure of heterodimeric mammalian FTase was determined at 2.25 angstrom resolution. The structure shows a combination of two unusual domains: a crescent-shaped seven-helical hairpin domain and an alpha-alpha barrel domain. The active site is formed by two clefts that intersect at a bound zinc ion. One cleft contains a nine-residue peptide that may mimic the binding of the Ras substrate; the other cleft is lined with highly conserved aromatic residues appropriate for binding the farnesyl isoprenoid with required specificity.
About this Structure
1FT1 is a Protein complex structure of sequences from Rattus norvegicus. Full crystallographic information is available from OCA.
Reference
Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution., Park HW, Boduluri SR, Moomaw JF, Casey PJ, Beese LS, Science. 1997 Mar 21;275(5307):1800-4. PMID:9065406
Page seeded by OCA on Sun Mar 30 20:29:42 2008
